Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Definitive Healthcare debuts data-agnostic analytics platform for life sciences applications 

By Brian Buntz | March 18, 2022

Definitive HealthcareDefinitive Healthcare (Nasdaq:DH) has launched the Passport Analytics Suite, a product line intended to facilitate the development, launch and commercialization of life science products.

The Passport Analytics Suite integrates technology from Framingham, Massachusetts-based Definitive Healthcare’s acquisition of Analytical Wizards in February 2022. Analytical Wizards is an advanced analytics company catering to the healthcare market. Having been branded as a ‘Definitive Healthcare company,’ Analytical Wizards will remain a standalone company,

One notable customer of Analytical Wizards is Sanofi (Nasdaq:SNY), which uses its technology to integrate data and run analytics at scale to drive strategic decision-making.

Similarly, the Passport Analytics Suite provides life sciences organizations with tools to establish an analytics-driven on-demand environment at scale.

“With these tools, clients can effectively assess and optimize brand performance and dial in the optimal promotional mix,” said Jason Krantz, founder and CEO of Definitive Healthcare, in a press release. “The Passport Analytics Suite helps clients optimize the entire commercialization process, from early-stage business planning needs through post-launch performance acceleration.”

The Passport Analytics Suite can incorporate data from either cloud or IT infrastructure.

“The Passport Analytics Suite is unique in its ability to combine AI-driven data science methodologies with deep expertise in the life sciences,” said Ram Sharma, founder and CEO of Analytical Wizards. “The Passport Analytics Suite delivers configurable analytics on-demand, allowing clients to cut and re-cut data as they want in a secure, self-service environment. The easy-to-use products enable team members from across an organization to create value by reporting on a single source of truth, and then looking at it from multiple angles.”


Filed Under: Data science
Tagged With: Definitive Healthcare, Passport Analytics Suite
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Xaira and Verily co-founder ponders low-hanging fruit and blue-sky potential in FDA’s genAI rollout
Capgemini’s life-sciences lead says ROI and data security, not algorithms, will decide pharma’s AI future
Portrait of happy smiling mature middle aged professional business woman investor manager executive or lawyer attorney looking at camera at workplace working on laptop computer in office.
As FDA pushes agency-wide generative AI, pharma experience show similar tools can cut clinical study-report drafting time by 30% or more
FDA’s genAI push could save CDER hundreds of thousands of review hours annually
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE